Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product in six additional markets. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, significantly expanding the company's international footprint. Each partnership is with a separate company and pertains to an individual market, with minimum purchase quantities agreed in each contract. Based on these agreements, Viromed anticipates additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It is intended for use in hospitals, private practices, and by surgically active medical specialists. The device represents a pioneering approach in dermatological care, offering a non-invasive treatment option that harnesses the antimicrobial and wound-healing properties of cold plasma.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented on the expansion: “With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks.”
These new agreements build on Viromed's existing international distribution network, which already includes an exclusive distribution agreement with UMECO covering ten Asian countries and a partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. The company's strategic focus on expanding its global presence is driven by the increasing adoption of cold plasma technology in medical applications, particularly in dermatology and wound care.
The significance of this announcement lies in Viromed's ability to penetrate new geographies, which is expected to contribute to its revenue growth and market share. By securing minimum purchase quantities, the company has guaranteed a baseline of sales, providing financial predictability. Furthermore, the expansion into Saudi Arabia and the Balkan region opens doors to emerging healthcare markets where demand for advanced medical devices is on the rise.
According to industry analysts, the global cold plasma market is projected to grow substantially in the coming years, driven by technological advancements and increasing awareness of its benefits. Viromed's proactive approach to forging distribution partnerships positions it well to capitalize on this trend. The company's pipeline includes potential collaborations in other countries, with announcements expected soon, indicating a sustained momentum in its internationalization strategy.
Viromed Medical AG has been listed on the stock exchange since October 2022 and operates through its wholly owned subsidiary Viromed Medical GmbH. The company focuses on the development, manufacture, and distribution of medical products, with a strong emphasis on cold plasma technology. With a broad customer base in the DACH region and beyond, Viromed aims to further advance the use of cold plasma in medicine and realize the corresponding growth potential.
